Skip to main content

Juan Bañares Sanchez

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Juan Bañares Sanchez

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Non-invasive assessment of cACLD and CSPH

IP: Joan Genescà Ferrer
Collaborators: Juan Bañares Sanchez
Funding agency: Hospital Universitari Vall d'Hebron
Funding: 35000
Reference: AULA/2024/BAÑERAS
Duration: 01/06/2024 - 31/05/2025

Caracterización de las claves fisiopatológicas y fenotipos de la enfermedad del hígado graso metabólica con ingesta moderada de alcohol para identificar nuevas terapias (ReLiveR).

IP: Meritxell Ventura Cots
Collaborators: Immaculada Raurell Saborit, Juan Manuel Pericàs Pulido, Laura Puente Ramo, Ares Aurora Villagrasa Vilella, Juan Bañares Sanchez, Maria de la Serra Cusidó Sabidó, Maria Martínez Gómez
Funding agency: Instituto de Salud Carlos III
Funding: 183920
Reference: PI22/01770
Duration: 01/01/2023 - 31/12/2025

StopALD

IP: Meritxell Ventura Cots
Collaborators: Juan Manuel Pericàs Pulido, Sonia Carramiñana Mayor, Juan Bañares Sanchez
Funding agency: Ajuntament Barcelona
Funding: 119700
Reference: AJUNT.BCN/CIENCIA_INNOV/2022/VENTURA
Duration: 08/12/2022 - 07/06/2024

Screening for liver fibrosis - population-based study across European countries

IP: Juan Manuel Pericàs Pulido
Collaborators: Joan Genescà Ferrer, Maria Francesca Cortese, Laura Puente Ramo, Juan Bañares Sanchez
Funding agency: EUROPEAN COMMISSION
Funding: 172385.95
Reference: LIVERSCREEN_H2020SC1BHC2019
Duration: 01/01/2020 - 30/06/2025

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Mariel Rojas Lora

Mariel Rojas Lora

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Read more
Li , Jiahui

Li , Jiahui

Research technician
Stroke research
Read more
Joaquin Lopez Soriano

Joaquin Lopez Soriano

P Management and Admin. Project manager
Clinical Trials Management Unit
Clinical Research Development Directorate
Read more
Balbastre Ubeda, Ferran

Balbastre Ubeda, Ferran

Research technician
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.